

# Loan Amend-and-Extends Revisited

*Originally published in the U.S. Credit Alpha on January 22, 2010*

## Introduction

Since the last time we addressed amend-and-extends,<sup>1</sup> loan prices have surged toward par. Although higher prices reduce the potential upside in extension candidates, many compelling opportunities exist, whether in the loan tranches of issuers that have executed an extension or in correctly identifying future extension. In general, when choosing between the stub and extended tranches, investors need to consider the credit outlook, relative tranche economics, and breakevens based on repayment speeds. Extended tranches provide the option of earning higher carry through either Libor floors or sweetened coupons. However, given that most extended tranches are trading over par, there is negative convexity, as loans with little call protection could be taken out at par and refinanced at lower spreads. Alternatively, staying in the unextended stub tranches that still trade under par provides investors a better convexity profile, as the option of early repayment may be more valuable in an improving economic environment.

This article highlights the relative value in the stub and extended tranches of a few issuers that have already extended their loans. Generally, we expect extended tranches that are trading under par to outperform the stubs, provided that the latter are not called inside the breakeven point and the credit outlook is positive. We also update our list of extension candidates by employing the criteria from our prior publication.

Approximately \$36.9bn in U.S. institutional loans were extended in 2009, generally resulting in better valuations for the original loan after the extension announcement. Fifty-five institutional revolvers and 40 term loan extensions were launched, with 47 and 37 approved, respectively. The average revolver was extended 2 years for a spread increase of 162bp and an associated amendment fee of 32bp. The average term loan was extended 2.2 years, for a spread increase of 166bp and an amendment fee of 29bp (Figure 1).

**Figure 1: 2009 Summary of Institutional Extensions Launched and Approved**

	Launched	Approved	Including a Libor Floor	Average Extension (Years)	Average Spread Increase (bp)	Average Amendment Fee (bp)
Revolvers	55	47	13	2.0	162	32
Institutional	40	37	12	2.2	166	29

Source: S&P LCD, Barclays Capital

<sup>1</sup> Please refer to our previous article on loan extensions, "Loan: Amend and Extends" (U.S. Credit Alpha, July 31, 2009), for loan extension mechanics, candidate screening criteria, and CLO indenture restrictions and managerial incentives.

## High Yield & Leveraged Loan Strategy

Gautam Kakodkar  
+1 212 412 7937  
gautam.kakodkar@barcap.com


Bradley Rogoff  
+1 212 412 7921  
bradley.rogoff@barcap.com

Michael Anderson  
+1 212 412 7936  
michael.anderson@barcap.com

www.barcap.com


Extensions were typically associated with par paydowns of existing tranches, some form of covenant relief, and Libor floor additions. Sponsors were actively involved, launching 60% of the amend-and-extends undertaken. For a sufficient spread increase, loan extensions, covenant amendments, and waivers were successfully completed and provided stressed companies with some runway. Even some lower quality companies were able to complete amend-and-extends in 2H09 (Figure 2). With the loan market rally and the opening of the primary markets, the spread increase offered for amendments has declined (Figure 3). Increasing investor appetite has caused new issue spreads to compress, and deals are often being reverse flexed. We have also recently seen secondary loans re-price lower, especially the expensive DIPs from last year's vintage, to the chagrin of lenders. Downward re-pricing of existing extended tranches could dampen amend-and-extend activity.

Figure 2: Institutional Amend-and-Extends by Quality—1H09 versus 2H09



Note: Data for CCC loans in 1H09 are not available. Source: S&P LCD


Figure 3: Amendment Spread Increases



Note: X-axis displays year/quarter and number of amendments in parenthesis. Data for Waiver/Forbearance are not applicable in 4Q09. Source: S&P LCD


Loan maturities are modest over the next two and a half years, so there is time to undertake the extension trade of the \$412bn of loans and \$254bn of bonds maturing between 2012 and 2014. **Although high yield bond takeouts, paydowns, loan issuance, and defaults are expected to address a portion of the maturities, we believe loan extension is an important tool, allowing the market to push out the loan refinancing cliff.** As discussed in our *U.S. Credit Market Outlook* (December 12, 2009), the performing institutional loan market has been dramatically reduced (by 18%), to \$470bn from \$582bn, with defaults accounting for 41% of the decline and the rest coming from paydowns. Maturities in 2010-11, consist of only \$87bn in bonds and \$14bn in institutional loans. However, further out, institutional loan maturities are concentrated, with \$412bn in 2012-14, while their associated pro rata revolvers mostly expire in 2011-13. In contrast, high yield bond maturities are more evenly ladder over the next few years (Figures 4 and 5).

**Figure 4: The Leverage Finance Maturity Wall**



Source: S&P LCD, Barclays Capital

**Figure 5: Institutional Loan Maturity Changes in 2009**



Source: S&P LCD, Barclays Capital

## CLO Participation in Extensions

CLOs have actively participated in the extensions and will continue to play an important role in refinancing the loan maturity wall. Indenture restrictions and managerial incentives have been determining factors in gauging CLO interest in extending loan maturities.

As discussed in our article “Loan Demand from Secondary CLOs” (*U.S. Credit Alpha*, January 15, 2010), CLO deals will face trading restrictions after the reinvestment period because of the failure of either coverage tests or the MDC (Moody’s downgrade condition). However, we believe there is nothing to prevent CLOs from participating in loan extensions. **While there has been some debate about whether or not CLOs past their reinvestment period can participate in loan extensions, our interpretation of most deal indentures is that they can.** In fact, many CLOs that are past their reinvestment period have already participated in loan extensions. The higher the spread increase offered, the greater the participation in rolling from the stub to the extended tranche.

Managerial incentives are also aligned. **We find that loan amendments, which allow for an extension of loan maturities in exchange for higher yields, have been widely accepted by CLO managers.** From a sample of 30 loans that were extended in 2009, CLOs chose to convert 50% of their exposure from the old into the new loans. We believe the conversion percentage would have been higher had the issuers offered to extend a greater portion of the original loan.

## Stub and Extended Tranche Performance Post-Extension

As discussed in our previous article, “Loan: Amend and Extends” (*U.S. Credit Alpha*, July 31, 2009), loans usually jump a couple points in price after the extension announcement. Also, upon extension, the extended tranche trades 2-3pts higher than the stub tranche. From an investor standpoint, we saw the best trading opportunity as owning the loans and shorter-dated discount bonds of loan extension candidates that are likely to be eclipsed by the extended loan maturity.

We now go a step further, analyzing the tradeoff between the stub and the extended tranches. We studied the relative post-extension performance of the stub and extended tranches of a representative sample of loans (Figure 6). In our sample, the stubs rallied from an average price of \$95 to \$98, while the extended tranches rose from \$97 to \$100. **Decomposing the price and coupon returns for the tranches from the extension date through January 20, 2010, we see that the extended tranche outperforms the stub as a result of the higher carry (Figure 7).** This will remain true unless the stub is repaid before a breakeven point. In our base case, we assume that the breakeven point is the repayment period in which we are indifferent between owning the stub tranche and an extended tranche that is repaid in three years. The stub tranche will have to be repaid under 1y to be able to outperform an extended tranche that is called in 3y (Figure 8). Another caveat is that because most extended tranches are trading over par, there is negative convexity, as the loans could be taken out at par and refinanced at lower spreads. This phenomenon was exemplified this week as Warner Chilcott proposed repricing its loan to L+325bp (1.75% floor) from L+350 (2.25% floor).

Figure 6: Sample Universe of Institutional Loans Extended in 2009

Issuer	Announce Date	Extension Date	Stub Size \$mn	Extended Size \$mn	Stub Coupon L+	Extended Coupon L+	Stub Maturity	Stub Maturity
Cablevision	5/12/09	5/21/09	2,400	1,100	175	325	3/28/13	3/28/16
Graham Packaging	5/13/09	5/21/09	600	1,200	225	425	10/7/11	4/7/14
Atlantic Broad	5/21/09	6/5/09	119	325	225	475	9/1/11	6/1/13
Rockwood	5/28/09	6/9/09	136	946	275	425	7/30/12	7/30/14
SunGard	5/28/09	6/9/09	1,700	2,500	175	363	2/28/14	2/28/16
Georgia-Pacific	6/16/09	6/26/09	4,400	1,000	200	325	1/27/13	12/27/14
Select Medical	7/27/09	7/31/09	265	385	200	375	2/1/12	8/24/14
Cedar Fair	7/28/09	8/4/09	639	836	200	400	12/1/12	12/1/14
West Corp	8/10/09	8/19/09	1,300	1,000	238	388	10/1/13	7/24/16
Jarden	8/12/09	8/18/09	124	600	175	325	1/1/12	1/24/15
Par Weighted Average					221	395	5.3y	3.2y

Note: Extended tranches with Libor floor include Graham Packaging (250bp), Atlantic Broadband (200bp), and Rockwood (200bp). Select Medical has recently done an IPO to take out some debt; Graham Packaging is planning an IPO to repay some term loan debt; Jarden recently issued subordinated bonds to repay some debt; Cedar Fair is seeking \$1.25bn in new loans to take out existing debt at par in connection with its LBO by Apollo; initially, Cedar fair was attempting to keep existing loans in place by amending its change-of-control provision, which was triggered by the LBO. Source: Barclays Capital, S&P LCD, Creditsights. Barclays Capital is acting as financial advisor to Apollo Global Management on the potential acquisition of Cedar Fair by an affiliate of Apollo Global Management.

Figure 7: Aggregate Performance of the Stub versus Extended Tranches

	Coupon Return Stub	Price Return Stub	Total Return Stub	Coupon Return Extension	Price Return Extension	Total Return Extension
MV Weighted Average	1.3%	4.2%	5.5%	2.3%	3.5%	5.8%

Note: Market value weighted aggregate of sample universe; assumes 15% prepayment rate of stub and extended tranches from the extension date until January 20, 2010. Source: Barclays Capital

Figure 8: Relative Value of Stub and Extended Tranches

Repayment Year	Stub Tranche Yield to Call	Extended Tranche Yield to Call
0.5	6.3%	5.3%
1	4.7%	5.2%
2	4.0%	5.2%
3	4.3%	5.7%
Maturity	4.3%	6.6%

Note: Yield to call on tranches is the market-value weighted yield to call for our sample set from January 20, 2010, until called, using matched-maturity swap rates. Source: Barclays Capital

### The Stub versus Extended Tranche Trade-off

Investing in companies that have already executed amend-and-extend programs presents an interesting trade-off. When analyzing the relative value of the stub and extended loan tranches, investors need to consider the credit outlook, relative tranche economics, and breakevens based on repayment speeds.

- Credit outlook—generally, if investors are bearish on the credit, they should stay in the unextended stub, thereby limiting the downside in the case of credit deterioration or default. Bullish investors should generally prefer the extended tranche economics;

however, negative convexity exists if the loan is priced over par. So in some cases, bullish investors may prefer the stub, which could get repaid early with free cash flow.

- Relative tranche economics—extended tranches benefit from higher carry through either Libor floors or sweetened coupons, although the value of the floor declines in a rising rate environment. Meanwhile, the stub tranche provides better convexity, i.e., lower dollar price. As a result, speed of repayment is a critical element determining the relative value of the tranches.
- Convexity due to repayment speed—function of call protection, proximity to par, capital structure, and size of tranches
  - Given that most extended tranches are trading over par, there is negative convexity, as these loans could be taken out at par and refinanced at lower spreads if they have no call protection.
  - Staying in the unextended stub tranches that still trade below par provides investors a better convexity profile, as the option of early repayment may be more valuable in an improving economic environment and a robust primary market.
  - Relative sizes of the stub and extended tranches may determine repayment speeds. The smaller the tranche, the more likely it will be repaid earlier.

Calculating the breakeven repayment point and evaluating the stub and extended tranches based on these criteria is helpful in determining relative value. Our base case breakeven is determined by calculating how soon the stub tranche will have to be repaid to earn the same return as an extended tranche that is repaid in three years. Figure 9 illustrates the breakeven points for a sample of loans.

- Graham Packaging stub (\$100, \$600mn, L+225bp, 10/2011) is less attractive than the extended tranche, which is trading over par (\$101.25, \$1.2bn, L+425bp, 250bp Libor floor, 4/2014), because the breakeven requires immediate repayment of the stub. Despite the negative convexity of the extended tranche and the dearth of bonds in the capital structure that need to be refinanced, the extended tranche will probably not be repaid before the stub.

**Figure 9: Stub versus Extended Tranche Breakeven Points**

Repayment Year	Graham Packaging		Sungard		Jarden	
	Stub Tranche Yield to Call	Extended Tranche Yield to Call	Stub Tranche Yield to Call	Extended Tranche Yield to Call	Stub Tranche Yield to Call	Extended Tranche Yield to Call
0.25	2.5%	1.7%	14.4%	12.1%	10.2%	1.5%
0.5	3.3%	4.2%	9.0%	8.8%	6.9%	3.2%
0.75	3.3%	5.0%	7.0%	7.4%	5.5%	3.6%
1	3.3%	5.4%	5.9%	6.8%	4.8%	3.7%
2	NA	6.0%	4.5%	5.9%	NA	4.1%
3	NA	6.3%	4.6%	6.2%	NA	4.8%
Maturity	3.4%	6.4%	4.9%	7.1%	4.0%	5.8%

Note: Breakeven analysis assumes that the base case for extended tranche repayment is three years and uses matched-maturity swap rates. Source: Barclays Capital

- SunGard stub (\$97, \$1.7bn, L+175bp, 2/2014) is less attractive than the extended tranche, which is trading under par (\$98, \$2.5bn, L+363bp, no Libor floor, 2/2016), because the breakeven of the stub is inside 1y. Also, there are bonds in the capital structure that need to be addressed ahead of the loans.
- Jarden stub (\$98, \$124mn, L+175bp, 1/2012) is more attractive than the extended tranche, which is trading over par (\$101, \$600mn, L+325bp, no Libor floor, 1/2015). The negative convexity of the extended tranche, the relative size of the tranches, and the dearth of near-term bonds inside the stub loan maturity indicate that the stub will probably be repaid inside the breakeven of 1y.

### Potential Candidates for Loan Extensions

Given the favorable loan performance after the extension announcement and the discount to par with which many loans still trade, extensions still provide upside to investors. We screened the loan universe for candidates (using criteria outlined in our July 31, 2009 article, “Loan: Amend and Extends,” *U.S. Credit Alpha*) and identified several names that are likely to attempt a loan extension (Figure 10). Although some of these candidates may attempt or have already done a partial refinancing, they still have sizeable near-term loan maturities, and there is still potential upside in the loans through either an extension or a paydown.

Figure 10: Potential Candidates for Loan Extensions

Issuer	1st Institutional Term Loan Maturity Date	Total Size All Institutional Tranches (\$ mn)	Price (\$)
Supervalu	2011	1,530	98
Dean Foods	2012	3,147	98
Infor Global Solutions	2012	4,648	94
Reynolds & Reynolds	2012	2,135	96
Hertz	2012	1,612	98
Toys R Us	2012	800	99
Avis Budget Car Rental	2012	778	98
Freescale	2013	3,380	90
Michaels Stores	2013	2,280	92
Carestream Health	2013	1,750	95
Neiman Marcus	2013	1,598	93
Burlington Coat	2013	865	95
Sally Beauty	2013	864	98

Source: Barclays Capital

#### Explanation of the High Grade Sector Weighting System

**Overweight:** Expected six-month excess return of the sector exceeds the six-month expected excess return of the Barclays Capital U.S. Credit Index or Pan-European Credit Index, as applicable.

**Market Weight:** Expected six-month excess return of the sector is in line with the six-month expected excess return of the Barclays Capital U.S. Credit Index or Pan-European Credit Index, as applicable.

**Underweight:** Expected six-month excess return of the sector is below the six-month expected excess return of the Barclays Capital U.S. Credit Index or Pan-European Credit Index, as applicable.

#### Explanation of the High Grade Research Rating System

The High Grade Research rating system is based on the analyst's view of the expected excess returns over a six-month period of the issuer's index-eligible corporate debt securities to the Barclays Capital U.S. Credit Index, the Pan-European Credit Index or the EM Asia USD High Grade Credit Index, as applicable.

**Overweight:** The analyst expects the issuer's index-eligible corporate bonds to provide positive excess returns relative to the Barclays Capital U.S. Credit Index, the Pan-European Credit Index, or the EM Asia USD High Grade Credit Index over the next six months.

**Market Weight:** The analyst expects the issuer's index-eligible corporate bonds to provide excess returns in line with the Barclays Capital U.S. Credit Index, the Pan-European Credit Index, or the EM Asia USD High Grade Credit Index over the next six months.

**Underweight:** The analyst expects the issuer's index-eligible corporate bonds to provide negative excess returns relative to the Barclays Capital U.S. Credit Index, the Pan-European Credit Index, or the EM Asia USD High Grade Credit Index over the next six months.

**Not Rated (NR):** An issuer which has not been assigned a formal rating.

**Rating Suspended (RS):** The rating has been suspended temporarily due to market events that make coverage impracticable or to comply with applicable regulations and/or firm policies in certain circumstances including where Barclays Capital is acting in an advisory capacity in a merger or strategic transaction involving the company.

For Japan and Australia issuers, the ratings are relative to the Barclays Capital U.S. Credit Index or Pan-European Credit Index, as applicable.

#### Explanation of the High Yield Sector Weighting System

**Overweight:** Expected six-month total return of the sector exceeds the six-month expected total return of the Barclays Capital U.S. High Yield 2% Issuer Capped Credit Index, or the Pan-European High Yield 3% Issuer Capped Credit Index excluding Financials, as applicable.

**Market Weight:** Expected six-month total return of the sector is in line with the six-month expected total return of the Barclays Capital U.S. High Yield 2% Issuer Capped Credit Index or the Pan-European High Yield 3% Issuer Capped Credit Index excluding Financials, as applicable.

**Underweight:** Expected six-month total return of the sector is below the six-month expected total return of the Barclays Capital U.S. High Yield 2% Issuer Capped Credit Index or the Pan-European High Yield 3% Issuer Capped Credit Index excluding Financials, as applicable.

#### Explanation of the High Yield Research Rating System

The High Yield Research team employs a relative return based rating system that, depending on the company under analysis, may be applied to either some or all of the company's debt securities, bank loans, or other instruments. Please review the latest report on a company to ascertain the application of the rating system to that company.

**Overweight:** The analyst expects the six-month total return of the rated debt security or instrument to exceed the six-month expected total return of the Barclays Capital U.S. 2% Issuer Capped High Yield Credit Index, the Pan-European High Yield 3% Issuer Capped Credit Index excluding Financials, or the EM Asia USD High Yield Corporate Credit Index, as applicable.

**Market Weight:** The analyst expects the six-month total return of the rated debt security or instrument to be in line with the six-month expected total return of the Barclays Capital U.S. 2% Issuer Capped High Yield Credit Index, the Pan-European High Yield 3% Issuer Capped Credit Index excluding Financials, or the EM Asia USD High Yield Corporate Credit Index, as applicable.

**Underweight:** The analyst expects the six-month total return of the rated debt security or instrument to be below the six-month expected total return of the Barclays Capital U.S. 2% Issuer Capped High Yield Credit Index, the Pan-European High Yield 3% Issuer Capped Credit Index excluding Financials, or the EM Asia USD High Yield Corporate Credit Index, as applicable.

**Not Rated (NR):** An issuer which has not been assigned a formal rating.

**Rating Suspended (RS):** The rating has been suspended temporarily due to market events that make coverage impracticable or to comply with applicable regulations and/or firm policies in certain circumstances including where Barclays Capital is acting in an advisory capacity in a merger or strategic transaction involving the company.

#### Analyst Certification(s)

We, Gautam Kakodkar, Bradley Rogoff and Michael H Anderson, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

#### Important Disclosures

For current important disclosures regarding companies that are the subject of this research report, please send a written request to: Barclays Capital Research Compliance, 745 Seventh Avenue, 17th Floor, New York, NY 10019 or refer to <https://ecommerce.barcap.com/research/cgi-bin/all/disclosuresSearch.pl> or call 212-526-1072.

Barclays Capital does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays Capital may have a conflict of interest that could affect the objectivity of this report. Any reference to Barclays Capital includes its affiliates. Barclays Capital and/or an affiliate thereof (the "firm") regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). The firm's proprietary trading accounts may have either a long and / or short position in such securities and / or derivative instruments, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, the firm's fixed income research analysts regularly interact with its trading desk personnel to determine current prices of fixed income securities. The firm's fixed income research analyst(s) receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the investment banking department), the profitability and revenues of the Fixed Income Division and the outstanding principal amount and trading value of, the profitability of, and the potential interest of the firms investing clients in research with respect to, the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays Capital trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. Barclays Capital produces a variety of research products including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research products, whether as a result of differing time horizons, methodologies, or otherwise.



This publication has been prepared by Barclays Capital, the investment banking division of Barclays Bank PLC, and/or one or more of its affiliates as provided below. This publication is provided to you for information purposes only. Prices shown in this publication are indicative and Barclays Capital is not offering to buy or sell or soliciting offers to buy or sell any financial instrument. Other than disclosures relating to Barclays Capital, the information contained in this publication has been obtained from sources that Barclays Capital believes to be reliable, but Barclays Capital does not represent or warrant that it is accurate or complete. The views in this publication are those of Barclays Capital and are subject to change, and Barclays Capital has no obligation to update its opinions or the information in this publication. Barclays Capital and its affiliates and their respective officers, directors, partners and employees, including persons involved in the preparation or issuance of this document, may from time to time act as manager, co-manager or underwriter of a public offering or otherwise, in the capacity of principal or agent, deal in, hold or act as market-makers or advisors, brokers or commercial and/or investment bankers in relation to the securities or related derivatives which are the subject of this publication.

The analyst recommendations in this report reflect solely and exclusively those of the author(s), and such opinions were prepared independently of any other interests, including those of Barclays Capital and/or its affiliates.

Neither Barclays Capital, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this publication or its contents. The securities discussed in this publication may not be suitable for all investors. Barclays Capital recommends that investors independently evaluate each issuer, security or instrument discussed in this publication and consult any independent advisors they believe necessary. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information in this publication is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This communication is being made available in the UK and Europe to persons who are investment professionals as that term is defined in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion Order) 2005. It is directed at, and therefore should only be relied upon by, persons who have professional experience in matters relating to investments. The investments to which it relates are available only to such persons and will be entered into only with such persons. Barclays Capital is authorized and regulated by the Financial Services Authority ('FSA') and member of the London Stock Exchange.

Barclays Capital Inc., US registered broker/dealer and member of FINRA ([www.finra.org](http://www.finra.org)), is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Subject to the conditions of this publication as set out above, ABSA CAPITAL, the Investment Banking Division of ABSA Bank Limited, an authorised financial services provider (Registration No.: 1986/004794/06), is distributing this material in South Africa. Any South African person or entity wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of ABSA Capital in South Africa, 15 ALICE LANE, SANDTON, JOHANNESBURG, GAUTENG, 2196. ABSA CAPITAL IS AN AFFILIATE OF BARCLAYS CAPITAL.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

In Japan, foreign exchange research reports are prepared and distributed by Barclays Bank PLC Tokyo Branch. Other research reports are distributed to institutional investors in Japan by Barclays Capital Japan Limited. Barclays Capital Japan Limited is a joint-stock company incorporated in Japan with registered office of 2-2-2, Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143.

Barclays Bank PLC Frankfurt Branch is distributing this material in Germany under the supervision of Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). This material is distributed in Malaysia by Barclays Capital Markets Malaysia Sdn Bhd.

IRS Circular 230 Prepared Materials Disclaimer: Barclays Capital and its affiliates do not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2010). All rights reserved. No part of this publication may be reproduced in any manner without the prior written permission of Barclays Capital or any of its affiliates. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.